Plain-English translation of NCT07076862 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers are using a new imaging tracer called [18F]F-AraG paired with PET/CT scans to map immune cell activity throughout the body in people with long-COVID (called PASC). The study includes 51 participants — some with ongoing long-COVID symptoms and some who recovered fully from COVID-19 — and will take pictures of how their immune systems are responding differently. Understanding these immune patterns may help doctors develop better ways to diagnose and monitor long-COVID in the future.
Long-COVID causes persistent symptoms across multiple body systems, and scientists believe ongoing immune system problems are at the root. This study exists to visualize and measure those immune changes directly, so researchers can understand what's happening biologically and create better diagnostic tools and treatments.
You likely qualify if…
You likely don't qualify if…
You will visit a research site for imaging scans where doctors inject a small amount of radioactive tracer and take detailed pictures of your whole body using a PET/CT scanner — this takes 60 to 90 minutes for the first scan, with some participants also returning 4 hours later for a second 30-minute scan. You'll also have blood drawn during your visit and answer questions about your symptoms. If you have long-COVID, you may be asked to come back for follow-up scans at 4 months and 8 months to see how your immune activity changes over time.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States